CANF and CFBI Related Headlines
Go Back- Can-Fite publishes study results on canine osteoarthritis drug
- Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
- Can-Fite advances pancreatic cancer drug to phase 2b trial
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
- Can-Fite reports phase 2a pancreatic cancer data for namodenoson
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
- Can-Fite BioPharma reports net loss widens to $9.83 million in 2025
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
- Can-Fite raises $4 million through warrant exercise agreement
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
- Can-Fite Provides Update on Clinical and Financial Status
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
- Can-Fite achieves 50% enrollment in pancreatic cancer drug trial
- Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
- Can-Fite prices $15 million public offering with institutional investor
- Can-Fite Announces Up To $15.0 Million Public Offering
CANF and CFBI Related Press Releases
Go Back- Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
- Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
- Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
- Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
- Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
- Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
- Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
- Can-Fite Provides Update on Clinical and Financial Status
- Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
- Pancreatic Cancer Phase 2a Study with Can-Fite’s Namodenoson Achieved Over 50% Enrollment Milestone
- Can-Fite Announces Up To $15.0 Million Public Offering
